MX2023009055A - Compuestos de secuestro para el tratamiento de un trastorno por uso de sustancias y usos de los mismos. - Google Patents
Compuestos de secuestro para el tratamiento de un trastorno por uso de sustancias y usos de los mismos.Info
- Publication number
- MX2023009055A MX2023009055A MX2023009055A MX2023009055A MX2023009055A MX 2023009055 A MX2023009055 A MX 2023009055A MX 2023009055 A MX2023009055 A MX 2023009055A MX 2023009055 A MX2023009055 A MX 2023009055A MX 2023009055 A MX2023009055 A MX 2023009055A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- substance use
- use disorder
- agents
- sequestration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163144441P | 2021-02-01 | 2021-02-01 | |
| PCT/US2022/014695 WO2022165407A1 (en) | 2021-02-01 | 2022-02-01 | Sequestration compounds for treatment of substance use disorder and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023009055A true MX2023009055A (es) | 2024-01-05 |
Family
ID=82654907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023009055A MX2023009055A (es) | 2021-02-01 | 2022-02-01 | Compuestos de secuestro para el tratamiento de un trastorno por uso de sustancias y usos de los mismos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12569478B2 (https=) |
| EP (1) | EP4284506A4 (https=) |
| JP (1) | JP2024506861A (https=) |
| KR (1) | KR20230167020A (https=) |
| CN (1) | CN117858728A (https=) |
| AU (1) | AU2022213437A1 (https=) |
| BR (1) | BR112023015462A2 (https=) |
| CA (1) | CA3207013A1 (https=) |
| IL (1) | IL304837A (https=) |
| MX (1) | MX2023009055A (https=) |
| WO (1) | WO2022165407A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020245535B2 (en) | 2019-03-26 | 2022-06-30 | Pinova Therapeutics Inc. | Devices and methods for delivering pharmaceutical compositions |
| CA3207013A1 (en) | 2021-02-01 | 2022-08-04 | Xinhua Li | Sequestration compounds for treatment of substance use disorder and uses thereof |
| US11278709B1 (en) | 2021-03-12 | 2022-03-22 | Pocket Naloxone Corp. | Drug delivery device and methods for using same |
| AU2024303746A1 (en) * | 2023-06-16 | 2026-01-22 | Clear Scientific, Inc. | Sequestrant compounds for alpha 2 adrenergic agonists |
| WO2025184478A1 (en) * | 2024-03-01 | 2025-09-04 | Temple University-Of The Commonwealth System Of Higher Education | Reversal agents for ultra-potent synthetic opioid-induced overdose and respiratory depression |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE375149T1 (de) * | 2003-07-25 | 2007-10-15 | Euro Celtique Sa | Behandlung von entzug |
| ES2702848T3 (es) * | 2011-02-23 | 2019-03-05 | Coeruleus Ltd | Complejos de flumazenil, composiciones que los comprenden y usos de los mismos |
| CA2875384A1 (en) * | 2013-12-20 | 2015-06-20 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
| US10874358B2 (en) * | 2015-12-22 | 2020-12-29 | Joseph Insler | Method and device for automatic identification of an opioid overdose and injection of an opioid receptor antagonist |
| IL312012A (en) * | 2016-11-18 | 2024-06-01 | Opiant Pharmaceuticals Inc | Compositions and methods for the treatment of opioid overdose |
| EP3833346A4 (en) * | 2018-08-08 | 2022-08-03 | Torralva Medical Therapeutics LLC | Compositions for opiate and opioid prevention and reversal, and methods of their use |
| CA3134674A1 (en) * | 2019-04-04 | 2020-10-08 | Intra-Cellular Therapies, Inc. | Methods of treating neuropathic pain |
| US10653690B1 (en) * | 2019-07-09 | 2020-05-19 | Orexo Ab | Pharmaceutical composition for nasal delivery |
| CA3207013A1 (en) | 2021-02-01 | 2022-08-04 | Xinhua Li | Sequestration compounds for treatment of substance use disorder and uses thereof |
-
2022
- 2022-02-01 CA CA3207013A patent/CA3207013A1/en active Pending
- 2022-02-01 AU AU2022213437A patent/AU2022213437A1/en active Pending
- 2022-02-01 CN CN202280024616.5A patent/CN117858728A/zh active Pending
- 2022-02-01 JP JP2023546560A patent/JP2024506861A/ja active Pending
- 2022-02-01 WO PCT/US2022/014695 patent/WO2022165407A1/en not_active Ceased
- 2022-02-01 BR BR112023015462A patent/BR112023015462A2/pt unknown
- 2022-02-01 MX MX2023009055A patent/MX2023009055A/es unknown
- 2022-02-01 EP EP22746860.0A patent/EP4284506A4/en active Pending
- 2022-02-01 KR KR1020237029974A patent/KR20230167020A/ko active Pending
- 2022-02-10 US US17/669,122 patent/US12569478B2/en active Active
-
2023
- 2023-07-30 IL IL304837A patent/IL304837A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022213437A9 (en) | 2024-07-11 |
| CN117858728A (zh) | 2024-04-09 |
| US20220313687A1 (en) | 2022-10-06 |
| CA3207013A1 (en) | 2022-08-04 |
| IL304837A (en) | 2023-09-01 |
| KR20230167020A (ko) | 2023-12-07 |
| AU2022213437A1 (en) | 2023-08-17 |
| EP4284506A4 (en) | 2024-12-25 |
| EP4284506A1 (en) | 2023-12-06 |
| JP2024506861A (ja) | 2024-02-15 |
| WO2022165407A1 (en) | 2022-08-04 |
| US12569478B2 (en) | 2026-03-10 |
| BR112023015462A2 (pt) | 2023-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023009055A (es) | Compuestos de secuestro para el tratamiento de un trastorno por uso de sustancias y usos de los mismos. | |
| DE60132710D1 (de) | 3-substituierte quinuclidin-derivate und deren verwendung als nikotinischen agonisten | |
| DE602008005928D1 (de) | 1h-indol-3-carbonsäure-chinuclidin-4-ylmethylesterderivate als liganden für den nikotinischen alpha-7-acetylcholinrezeptor zur behandlung von alzheimer-krankheit | |
| Crespo-Alonso et al. | Biomass against emerging pollution in wastewater: ability of cork for the removal of ofloxacin from aqueous solutions at different pH | |
| Neumeyer et al. | Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed κ agonists and μ agonists/antagonists as potential pharmacotherapeutics for cocaine dependence | |
| RU2009120674A (ru) | Амиды диазабициклоалканов, селективные в отношении ацетилхолинового подтипа никотиновых рецепторов | |
| RU2011129638A (ru) | Получение и применение моно- и ди-пэг il-10 | |
| DE602007004307D1 (de) | Enantiomerenreine chinuclidinyloxy-pyridazine und ihre verwendung als nikotin-acetylcholin-rezeptorliganden | |
| ATE287888T1 (de) | Aryl- und heteroaryldiazabicycloalkane, deren zubereitung und verwendung | |
| WO2011009890A2 (en) | Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives | |
| ATE481407T1 (de) | Neue diazabicyclische arylderivate und medizinische verwendung dafür | |
| MX2007004269A (es) | Derivados de arilo diazabiciclico nuevos y su uso medico. | |
| WO2006087306A3 (en) | Diazabicyclic aryl derivatives and their use as cholinergic ligands at the nicotinic acetylcholine receptors | |
| Sun et al. | Oxidation of theophylline by Ferrate (VI) and formation of disinfection byproducts during subsequent chlorination | |
| DK1963323T3 (da) | Hidtil ukendte diazabicykliske arylderivater og medicinsk anvendelse heraf | |
| ATE490958T1 (de) | Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate | |
| Fisher et al. | Design and synthesis of photoaffinity-labeling ligands of the L-prolyl-L-leucylglycinamide binding site involved in the allosteric modulation of the dopamine receptor | |
| DE60307102D1 (de) | 3-substituierte chinuklidine und deren verwendung | |
| AU2022246090B2 (en) | Enamine n-oxides: synthesis and application to hypoxia-responsive prodrugs and imaging agents | |
| Herbert et al. | Persistent phototransformation products of vardenafil (Levitra®) and sildenafil (Viagra®) | |
| BR0112130A (pt) | Composições farmacêuticas e métodos para uso | |
| RU2011127055A (ru) | Лекарственное средство для лечения неврологическо-поведенческих расстройств развития и способ лечения неврологическо-поведенческих расстройств развития | |
| Kruk et al. | Effects of the histamine H3 receptor antagonist ABT-239 on cognition and nicotine-induced memory enhancement in mice | |
| ATE460416T1 (de) | Neuartige 1,4-diazabicycloä3.2.2ünonan-derivate und deren medizinische verwendung | |
| MX2007003331A (es) | Nuevos derivados de arilo diazabiciclico. |